Mathematical Modeling of Strategic Treatments on Tumor Growth

Jyotsna Baloni; U. S. Rana

Authors

Jyotsna Baloni
U. S. Rana

mathematical modeling, chemotherapy, effector cell, il-2, adoptive immunotherapy

Abstract

We propose to contribute to the emerging body of cancer treatment research by developing and analyzing mathematical models of the treatment of tumor with various strategic treatments. We build on existing models of the immunology that are already successfully developed and then the effects of chemotherapy and interleukin-2 were applied to the model. Thus we build a mathematical model of tumour and effector cell with scheduled chemotherapy.The effect of scheduled il2 dose with chemotherapy and adoptive immunotherapy reduced the tumor growth.

Downloads

How to Cite

Mathematical Modeling of Strategic Treatments on Tumor Growth. (2014). Global Journal of Science Frontier Research, 14(F3), 91-99. https://www.journalofscience.org/index.php/GJSFR/article/view/1256

Download Citation

References

C Hsieh, D Chen, L Hwang (2000) Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. 11, 681-692.

K Smith (1988) Interleukin-2: inception, impact, and implications. 240, 1169-1176.

R Repmann, S Wagner, A Richter (1997) The use of interleukin 2 in the treatment of renal cell cancer and melanoma proved that an immunological treatment is capable, in some cases, of inducing long term regression of metastatic tumours. 17, 2879-2882.

Cancer chemotherapy.

R Martin, M Fisher, R Minchin, K Teo (1990) A mathematical model of cancer therapy with an optimal selection of parameters. 99(2), 205-230.

P Calabresi, P Schein (1993) Principles of Cancer Diagnosis and Staging. 10-21.

J Holland, Emil Frei, I (1973) Book Review Human Cancer . Arthur Purdy Stout, M.D. Lea and Febiger. Philadelphia, 1932. pp. 1007. Price $10.00.. 208(15), 817-817.

F Levi (2002) From circadian rhythms to cancer chronotherapeutics. 19(1), 1-19.

K Visser, W Kast (1999) Effects of TGF-β on the immune system: Implications for cancer immunotherapy. 13, 1188-1199.

Adelheid Cerwenka, Susan Swain (1999) TGF-β1: immunosuppressant and viability factor for T lymphocytes. 1(15), 1291-1296.

Denise Kirschner, John Panetta (1998) Modeling immunotherapy of the tumor - immune interaction. 37(3), 235-252.

Trachette Jackson (2002) Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support. 44(3), 201-226.

S Gardner (2000) A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and nonspecific drugs. 60, 1417-1425.

Avdeyev Sp, Milnov Gd, Botvina As (2008) Variation of the Source Velocity in Collisions of 2.1 GEV Protons with Gold Target. 1-2.

L Pillis, W Gu, A Radunskaya (2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. 238(4), 841-862.

V Kuznetsov, I Makalkin, M Taylor, A Perelson (1994) Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. 56(2), 295-321.

Judah Folkman, Mark Hochberg (1973) SELF-REGULATION OF GROWTH IN THREE DIMENSIONS. 138(4), 745-753.

T Loo, G Housholder, A Gerulath, P Saunders, D Farquhar (1976) Mechanism of action and pharmacology studies with DTIC (NSC-45388). 60, 149-152.

R Deboer, P Hogeweg, H Dullens, R De Weger, W Den Otter (1985) Macrophage T lymphocyte interactions in the anti-tumor immune response: A mathematical model. 134, 2748-2757.

Susan Mckarns, Norbert Kaminski (2000) TGF-β1 differentially regulates IL-2 expression and [3H]-thymidine incorporation in CD3ε mAb- and CD28 mAb-activated splenocytes and thymocytes. 48(2), 101-115.

T Tzai, A Shiau, L Liu, C Wu (2000) Immunization with TGF-β antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice trough upregulation of MHC Class I and Fas expressions. 20, 1557-1562.

Rik Derynck, Rosemary Akhurst, Allan Balmain (2001) TGF-β signaling in tumor suppression and cancer progression. 29(2), 117-129.

Steven Rosenberg, James Yang, Donald White, Seth Steinberg (1998) Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. 228(3), 307-319.

Galina Nerodo, Oksana Kravtsova, Vera Nikitina, Ekaterina Verenikina, Ivan Nikitin (2017) Results of treatment of serious ovarian cancer at the use of different schemes of neoadyuvant chemotherapy. 12(2).

Chemotherapy Principles-An In-depth Discussion of the Techniques and Its Role in Cancer Treatment.

(2011) High dose Interleukin-2.

J Massague (1998) TGF-β SIGNAL TRANSDUCTION. 67(1), 753-791.

T Holen, M Amarzguioui, M Wiiger, E Babaie, H Prydz (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. 30, 1757-1766.

Laura Alwan, Kenneth Grossmann, Daniel Sageser, Joan Van Atta, Neeraj Agarwal, Jeffrey Gilreath (2013) Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. 9(1), 63-71.